ArticleGenome medicine2026
VariantMedium: sensitive and generalizable somatic point mutation calling with 3D DenseNets trained and evaluated on experimental data.
Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurately identifying somatic variants from genomic sequencing is crucial for understanding and treating cancer. Previously, methods based on statistics and heuristics, as well as methods based on machine learning were proposed for somatic single nucleotide variant (SNV) calling from matched tumor-normal data, but they suffer from low sensitivity especially in certain genomic regions.
methodsHere we present VariantMedium, a somatic variant caller that combines a tree-based classifier with a 3D densely connected convolutional network (DenseNet) architecture. We trained and evaluated our model on experimentally confirmed variant data and improved it with an active learning strategy by experimentally confirming the predicted variants via targeted deep sequencing experiments. Overall, we used 336,839 variants from 2,956 samples with whole exome or genome sequencing for training and validation, and 118,887 variants from two independent studies with deep sequencing data for evaluation and benchmarking.
resultsVariantMedium shows highest sensitivity amongst benchmarked callers and achieves similar or better F1 scores in SNV calling. Its performance is particularly pronounced on genomic regions characterized by high sequencing error rates, achieving higher F1 scores than Mutect2 and Strelka2.
conclusionsOur results demonstrate the strength of combining machine learning with high-quality experimental confirmation, enabling accurate somatic mutation detection even in low-mappability regions. We provide VariantMedium ( https://github.com/TRON-Bioinformatics/VariantMedium ) as an end-to-end pipeline to advance somatic mutation calling for precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.